Published in Biochem Biophys Res Commun on November 12, 2004
The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol (2009) 2.23
Animal origins of the severe acute respiratory syndrome coronavirus: insight from ACE2-S-protein interactions. J Virol (2006) 1.91
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A (2007) 1.76
Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev (2007) 1.68
Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol (2011) 1.44
Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine (2014) 1.38
Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. J Virol (2013) 1.26
A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J Virol (2014) 1.23
Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J Virol (2008) 1.22
Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology (2009) 1.22
Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine. Chem Biol Drug Des (2009) 1.18
A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection. PLoS One (2013) 1.18
Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice. J Virol (2006) 1.12
A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses. PLoS One (2011) 1.08
Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design. Vaccine (2014) 1.07
Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain. J Virol (2005) 1.03
Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. J Virol (2006) 1.02
Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol Immunol (2015) 1.02
Virus pathogen database and analysis resource (ViPR): a comprehensive bioinformatics database and analysis resource for the coronavirus research community. Viruses (2012) 1.01
Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells. Biochem Biophys Res Commun (2009) 1.00
Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses. Expert Opin Biol Ther (2009) 0.98
A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity. Viral Immunol (2010) 0.98
Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus. J Clin Microbiol (2005) 0.94
SARS vaccine development. Emerg Infect Dis (2005) 0.90
Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV). J Pharm Pharm Sci (2008) 0.89
Receptor-binding domain-based subunit vaccines against MERS-CoV. Virus Res (2014) 0.88
Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. Virol J (2010) 0.86
Receptor-binding domain as a target for developing SARS vaccines. J Thorac Dis (2013) 0.85
Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. Rev Med Virol (2011) 0.83
Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Hum Vaccin Immunother (2013) 0.81
Molecular mechanisms of severe acute respiratory syndrome (SARS). Respir Res (2005) 0.81
Receptor-binding domain of SARS-Cov spike protein: soluble expression in E. coli, purification and functional characterization. World J Gastroenterol (2005) 0.80
Substitution at aspartic acid 1128 in the SARS coronavirus spike glycoprotein mediates escape from a S2 domain-targeting neutralizing monoclonal antibody. PLoS One (2014) 0.79
A vaccine of L2 epitope repeats fused with a modified IgG1 Fc induced cross-neutralizing antibodies and protective immunity against divergent human papillomavirus types. PLoS One (2014) 0.78
Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines. Emerg Microbes Infect (2012) 0.77
Primary severe acute respiratory syndrome coronavirus infection limits replication but not lung inflammation upon homologous rechallenge. J Virol (2012) 0.77
A combined nucleocapsid vaccine induces vigorous SARS-CD8+ T-cell immune responses. Genet Vaccines Ther (2005) 0.76
Protocol for recombinant RBD-based SARS vaccines: protein preparation, animal vaccination and neutralization detection. J Vis Exp (2011) 0.76
Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology. MAbs (2010) 0.76
A Sabin 1 poliovirus-based vaccine vector transfects Vero cells with high efficiency. Cytotechnology (2007) 0.75
Intranasal vaccination of recombinant H5N1 HA1 proteins fused with foldon and Fc induces strong mucosal immune responses with neutralizing activity: Implication for developing novel mucosal influenza vaccines. Hum Vaccin Immunother (2015) 0.75
Global research trends of World Health Organization's top eight emerging pathogens. Global Health (2017) 0.75
Identification of a Novel Inhibitor against Middle East Respiratory Syndrome Coronavirus. Viruses (2017) 0.75
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature (2003) 8.77
The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell (2009) 7.88
Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife (2012) 5.18
Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci U S A (2004) 5.15
Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe (2009) 5.12
Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science (2005) 4.97
A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem (2003) 3.60
H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science (2013) 3.33
Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog (2011) 3.26
Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A (2004) 3.23
The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat Rev Immunol (2012) 3.17
Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J (2005) 3.14
Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. Nature (2007) 3.06
Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell (2003) 3.03
N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob Agents Chemother (2004) 2.76
Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J Biol Chem (2006) 2.56
Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol (2002) 2.43
SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. J Biol Chem (2005) 2.36
The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol (2009) 2.23
Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell (2007) 2.22
Evolution of a TRIM5-CypA splice isoform in old world monkeys. PLoS Pathog (2008) 2.20
Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology (2005) 2.03
Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev (2008) 2.00
Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem (2005) 1.99
Ifitm3 limits the severity of acute influenza in mice. PLoS Pathog (2012) 1.97
Animal origins of the severe acute respiratory syndrome coronavirus: insight from ACE2-S-protein interactions. J Virol (2006) 1.91
Life expectancy among non-high school graduates. Health Aff (Millwood) (2013) 1.91
The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. Cell Host Microbe (2013) 1.86
Ligand-independent dimerization of CXCR4, a principal HIV-1 coreceptor. J Biol Chem (2002) 1.82
Influenza A virus neuraminidase limits viral superinfection. J Virol (2008) 1.79
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A (2007) 1.76
Genomic signature and mutation trend analysis of pandemic (H1N1) 2009 influenza A virus. PLoS One (2010) 1.75
Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem (2008) 1.74
Sulphated tyrosines mediate association of chemokines and Plasmodium vivax Duffy binding protein with the Duffy antigen/receptor for chemokines (DARC). Mol Microbiol (2005) 1.71
Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol (2005) 1.70
HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Curr Pharm Des (2007) 1.66
Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol (2004) 1.62
Genomic signature and protein sequence analysis of a novel influenza A (H7N9) virus that causes an outbreak in humans in China. Microbes Infect (2013) 1.59
Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. J Virol (2004) 1.58
HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. J Biol Chem (2007) 1.58
Pairing and phase separation in a polarized Fermi gas. Science (2005) 1.58
Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J Biol Chem (2006) 1.54
Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J Virol (2005) 1.54
Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R. J Biol Chem (2006) 1.53
TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine. PLoS Pathog (2013) 1.53
Mapping binding residues in the Plasmodium vivax domain that binds Duffy antigen during red cell invasion. Mol Microbiol (2005) 1.52
Research and development of universal influenza vaccines. Microbes Infect (2010) 1.49
Receptor determinants of zoonotic transmission of New World hemorrhagic fever arenaviruses. Proc Natl Acad Sci U S A (2008) 1.47
Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion. Angew Chem Int Ed Engl (2002) 1.47
Structural basis for receptor recognition by New World hemorrhagic fever arenaviruses. Nat Struct Mol Biol (2010) 1.46
Determination of the HIV-1 gp41 fusogenic core conformation modeled by synthetic peptides: applicable for identification of HIV-1 fusion inhibitors. Peptides (2003) 1.41
IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus. J Virol (2013) 1.39
Host-species transferrin receptor 1 orthologs are cellular receptors for nonpathogenic new world clade B arenaviruses. PLoS Pathog (2009) 1.37
Structural basis for activation and inhibition of the secreted chlamydia protease CPAF. Cell Host Microbe (2008) 1.36
Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2. J Virol (2004) 1.36
Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine (2006) 1.36
Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry. J Biol Chem (2007) 1.34
Conformational states of the severe acute respiratory syndrome coronavirus spike protein ectodomain. J Virol (2006) 1.34
Molecular determinants of enterovirus 71 viral entry: cleft around GLN-172 on VP1 protein interacts with variable region on scavenge receptor B 2. J Biol Chem (2012) 1.33
Protein evolution with an expanded genetic code. Proc Natl Acad Sci U S A (2008) 1.32
Microbicides: stopping HIV at the gate. Lancet (2006) 1.31
Spin-imbalance in a one-dimensional Fermi gas. Nature (2010) 1.30
A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. J Infect (2012) 1.28
Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2. J Virol (2004) 1.28
Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J Immunol (2006) 1.27
Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. J Virol (2014) 1.27
An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J (2010) 1.26